View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 2, 2020updated 12 Jul 2022 11:39am

BMS reports positive interim data from Phase III trial of Zeposia

Bristol Myers Squibb (BMS) has reported positive interim results from the Phase III DAYBREAK open-label extension clinical trial of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).

Bristol Myers Squibb (BMS) has reported positive interim results from the Phase III DAYBREAK open-label extension clinical trial of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Data showed the long-term efficacy and safety profile of the drug, reported BMS.

Zeposia is an oral, sphingosine 1-phosphate (S1P) receptor modulator designed to bind with high affinity to S1P receptors 1 and 5.

The drug inhibits the ability of lymphocytes to egress from lymph nodes, decreasing the number of lymphocytes in peripheral blood.

DAYBREAK enrolled 2,494 patients who had completed a Phase I, II or III study of Zeposia, with an average treatment time of 35.4 months in DAYBREAK. The primary objective was safety in the overall population.

No new safety concerns were observed in the DAYBREAK study upon long-term use of the drug.

At months 24 and 36, 79% and 75% of subjects were relapse-free, respectively. Three and six month disability progression was reported in 10.8% and 8.6% of patients, respectively.

The average number of new/enlarging T2 lesions and gadolinium-enhanced (GdE) lesions per scan at 24 months were found to be similar, irrespective of the parent-trial treatment arm.

Of the 2,494 patients treated with Zeposia in DAYBREAK for 35.4 months, 2,039 subjects experienced a treatment-emergent adverse event (TEAE), 236 had a serious TEAE (SAE), and 56 discontinued the trial due to a TEAE.

The most common TEAEs were nasopharyngitis, headache, upper respiratory tract infection, and lymphopenia.

Bristol Myers Squibb Immunology and Fibrosis Development head Mary Beth Harler said: “Alongside our industry-leading collaborators, we are investigating novel endpoints, brain volume and cognition, which may help to further our understanding of the safety and efficacy profile of Zeposia and can advance transformational science for multiple sclerosis patients experiencing this unpredictable, debilitating disease.”

Last month, BMS said that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care failed to meet the primary endpoint of overall survival in acute myeloid leukemia patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena